Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203839 | 0.87 | CYP1A2 (0.46) | TRPV3 | |
| SCHEMBL5205299 | 0.73 | KIT (0.39) | BRD4MPOSCDKCNH2CETP | |
| SCHEMBL5202727 | 0.72 | TRPV3 (0.46) | TRPV3S1PR1 | |
| SCHEMBL7007726 | 0.72 | CYP1A2 (0.51) | — | |
| SCHEMBL9161561 | 0.72 | PDE4B (0.49) | S1PR1KCNH2 | |
| SCHEMBL6182752 | 0.71 | NPSR1 (0.55) | — | |
| SCHEMBL14983665 | 0.70 | KCNH2 (0.47) | S1PR1KCNH2PIM1 | |
| SCHEMBL5207531 | 0.69 | RAB9A (0.46) | — | |
| SCHEMBL5009648 | 0.69 | DAO (0.55) | MPOCETP | |
| SCHEMBL5204620 | 0.68 | LMNA (0.45) | TRPV3S1PR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | claimed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | claimed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | claimed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | claimed |
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | disclosed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | PYM1, Q6ZSR9, MRM1 | STAT3 4320/4885ROCK1 409/4885ROCK2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.